Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	1.74B
Revenue (ttm)	216.90M
Net Income (ttm)	-61.50M
Shares Out	16.55M
EPS (ttm)	-3.75
PE Ratio	n/a
Forward PE	160.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,999
Average Volume	25,007
Open	106.00
Previous Close	105.00
Day's Range	102.00 - 106.00
52-Week Range	90.20 - 145.00
Beta	0.78
RSI	32.05
Earnings Date	Apr 2, 2025

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as acce...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 119
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.